


SURVIVAL BENEFIT WITH LENALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH MYELOMA: AREA UNDER THE CURVE-BASED REANALYSIS CP-148





67.5% patients included & 47 months of follow-up,

PFS = 2.7 months (17.0 vs. 14.3)



43.5% patients analyzed & 50 months of follow-up

OS = 5.3 months (25.5 vs. 20.2)

CONCLUSIONS

AUC-based analysis showed a shorter survival benefit than the difference in median survival.

This is probably related to the shape of the curves, which diverged at the medium zone of the graph.

OS reanalysis is very limited because the observation time is insufficient to provide mature data.